Zynex, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2021
November 02, 2021 at 04:02 pm EDT
Share
Zynex, Inc. provided earnings guidance for the fourth quarter and full year 2021. The estimated range for fourth quarter revenue is between $40.0 and $43.0 million. The revenue estimate is approximately 56% to 68% above 2020 fourth quarter revenue of $25.6 million.
Full year 2021 revenue is estimated between $130.0 and $133.0 million. The full year revenue estimate is approximately 62% to 66% above 2020 revenue of $80.1 million.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
